FIH Mobile : CHANGE OF EXECUTIVE DIRECTOR AND CHANGE OF CORPORATE GOVERNANCE COMMITTEE MEMBER

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FIH Mobile Limited 富智康集團有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 2038)

CHANGE OF EXECUTIVE DIRECTOR

AND

CHANGE OF CORPORATE GOVERNANCE COMMITTEE MEMBER

The Board hereby announces the following changes with effect from 29 June 2018:

• 1. Dr. KUO Wen-Yi has been appointed as an executive director and a member of the corporate governance committee of the Company; and

• 2. Mr. HUANG Chin Hsien has resigned as an executive director and a member of the corporate governance committee of the Company.

The board of directors (the "Board") of FIH Mobile Limited (the "Company", and together with its subsidiaries, the "Group") hereby announces that with effect from 29 June 2018, Dr. KUO Wen-Yi ("Dr. Kuo") has been appointed as an executive director of the Company and a member of the corporate governance committee of the Company, and Mr. HUANG Chin Hsien ("Mr. Huang") has resigned as an executive director of the Company and ceased to act as a member of the corporate governance committee of the Company due to his desire to spend more time with his family; however, Mr. Huang would remain as a director of certain subsidiaries of the Company until the effective dates on which the nominated replacement directors could take up such directorships.

Mr. Huang has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company.

Pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules"), the personal particulars of Dr. Kuo are as follows:

Dr. KUO Wen-Yi, Chinese American, aged 52, joined the Group in December 2014 and is currently the vice president of the Group. He is also a director of ICI Cayman Limited and a supervisor of 深圳市 富 宏 訊 科 技 有 限 公 司 (Shenzhen Fu Hong Xun Technology Co., Ltd.*) respectively, both being subsidiaries of the Company. Dr. Kuo has more than 23 years of extensive experiences in wireless communication product research and development, international business development, startup business and corporate management. Before joining the Company in December 2014, Dr. Kuo was the founder and the chief executive officer of BandRich Inc. ("BandRich") from March 2006 to December 2014. The core businesses of BandRich were product development and sales of 3.5G (also known as High Speed Downlink Packet Access (HSDPA)) and 4G LTE (the Fourth Generation of Mobile Phone Mobile Communication Technology Standards Long-Term Evolution) wireless routers and communication modules for home, vehicle and outdoor applications. BandRich partnered with the world's dominant wireless infrastructure suppliers Ericsson and Alcatel-Lucent and sold products to worldwide operators. From April 2003 to February 2006, Dr. Kuo was the senior director (department head) of Compal Electronics Inc. (a listed company in Taiwan) and was in charge of the business in 3G (the Third Generation of Wireless Mobile Telecommunications Technology) mobile phone.

From May 2000 to July 2002, Dr. Kuo was the co-founder and the chief technology officer of Wiscom Technologies ("Wiscom") in New Jersey, USA. Wiscom was focusing on development of 3G mobile phone baseband chip. Wiscom's intellectual property rights were later acquired by Intel Corporation. From April 1999 to May 2000, Dr. Kuo was the principal technical staff member of AT&T Labs, engaged in 3G WCDMA (Wideband Code Division Multiple Access) system researches. From January 1995 to April 1999, Dr. Kuo worked in Bell Laboratories of Lucent Technologies on CDMA (Code Division Multiple Access) and WCDMA research and development on network infrastructures. Dr. Kuo is the inventor of 38 USA wireless communications patents. He received the IEEE (Institute of Electrical and Electronics Engineers) Leonard G. Abraham Prize in 2001. He was an adjunct professor at New Jersey Institute of Technology in 1998. Dr. Kuo received a Bachelor Degree of Science in Communications Engineering from National Chiao Tung University, Taiwan in 1987, a Master Degree of Science in Electrical Engineering from National Taiwan University in 1989, and a Doctoral Degree of Philosophy in Electrical Engineering from Purdue University, USA in 1994.

Save as disclosed herein, Dr. Kuo did not hold other positions with the Company or other members of the Group, nor did he have any relationships with any directors, senior management or substantial or controlling shareholders of the Company. Dr. Kuo did not hold any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years.

As at the date of this announcement, Dr. Kuo has personal interest in 2,310 shares and family interest (representing the interest held by Ms. Yu-Yin Emily KAO, the spouse of Dr. Kuo, in which Dr. Kuo shall be deemed or taken to be interested for the purposes of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "SFO")) in 17 shares of 鴻 海 精 密 工 業 股 份 有 限 公 司 (Hon Hai Precision Industry Co. Ltd.*). Save as disclosed above, as at the date of this announcement, Dr. Kuo does not have any other interest in the shares and/or underlying shares of the Company or its associated corporations within the meaning of Part XV of the SFO.

Dr. Kuo has been appointed for a term of three years commencing from 29 June 2018 and ending on 28 June 2021 (both dates inclusive), subject to retirement and re-election under the articles of association of the Company. He has entered into a director's service contract with the Company and will be entitled to an annual emoluments package of US$500,000 and a discretionary bonus to be determined by the Board from time to time with reference to the Company's performance, his duties and responsibilities with the Company, his contribution to the Company and the prevailing market practice.

Save as disclosed above, there is no information which is discloseable nor is Dr. Kuo involved in any of the matters required to be disclosed pursuant to any of the requirements of the provisions under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and there is no other matter which needs to be brought to the attention of the shareholders of the Company.

The Board would like to express its gratitude to Mr. Huang for his valuable contribution to the Group during his tenure of office and also extend its warmest welcome to Dr. Kuo for joining the Board.

By Order of the Board

CHIH Yu Yang Acting Chairman

Hong Kong, 29 June 2018

As at the date of this announcement (after trading hours), the Board of the Company comprises three executive directors, namely Mr. CHIH Yu Yang, Mr. WANG Chien Ho and Dr. KUO Wen-Yi; one non-executive director, namely Dr. LUO Zhongsheng; and three independent non-executive directors, namely Mr. LAU Siu Ki, Dr. Daniel Joseph MEHAN and Mr. TAO Yun Chih.

*For identification purposes only